PHASE I/II STUDY LADARIXIN AND SOTORASIB IN ADVANCED KRAS G12C MUTANT NON-SMALL CELL LUNG CANCER (NSCLC).

Go Back to All Clinical Trials

PHASE I/II STUDY LADARIXIN AND SOTORASIB IN ADVANCED KRAS G12C MUTANT NON-SMALL CELL LUNG CANCER (NSCLC).

Brief description of study

This is a phase I/II, open-label, study of twice-daily oral ladarixin with sotorasib in subjects with advanced KRAS G12C mutant NSCLC.

Clinical Study Identifier: s22-00959

ClinicalTrials.gov Identifier: NCT05815173

Principal Investigator: Salman Rafi Punekar.

Other Investigators: Jessica Wang, Elaine Shum, Sally Lau, Joshua K Sabari, Marissa Rybstein, David Mendoza, Melissa L Martinez, Vamsidhar Velcheti, Jeffrey G Schneider, Natalia Cherkassky, Kirby Rodriguez.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies